Keryx Biopharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Keryx Biopharmaceuticals Inc.
ElevateBio Raises $401m To Fund Its Own And Partners’ Future Cell And Gene Therapy Needs
ElevateBio closed a series D venture capital round and revealed a potentially multibillion-dollar deal between its Life Edit subsidiary and Novo Nordisk as demand for its cell and gene therapy capabilities grow.
Back From The Dead Biodexa Makes Bid For VarianBio
Having just avoided going into administration, the firm formerly known as Midatech has pivoted its business model from a drug delivery company to a therapeutics player and has hit the acquisition trail.
Stock Watch: Pfizer Gets Back To Business As Usual
Sales Of Pfizer’s pandemic products decline as other vaccines are scheduled for a second-half launch but the road back to 2022’s all-time high in annual revenues will not be easy.
Down But Not Out: Nichi-Iko Hives Off Sagent, Exits North America
Seven years after it paid almost three quarters of a billion dollars for US-based Sagent, troubled Nichi-Iko is offloading the struggling business.
- Other Names / Subsidiaries
- Access Oncology
- AOI Pharma, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.